Dr. Elmaleh is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachusetts General Hospital. He is a renowned molecular imaging expert and inventor of numerous molecular imaging agents including three drugs that are in use in man or in late stage clinical trials, including the radiopharmaceutical preparation of (2FDG) which has been used in millions of PET imaging procedures. Dr. Elmaleh also recently received patent protection for the use of 18F-FDG PET for imaging atherosclerosis, for tracking inflammation within plaques, and for monitoring the response to drug therapy; a promising use that should be part of the future diagnostic armament. Dr. Elmaleh’s extensive research of the metabolic trapping of fatty acids and other imaging-designed drugs was a pivotal turning point in the development of molecular imaging. Influenced by the ingenious mathematical model developed by Dr. Louis Sokoloff for measuring brain glucose, Dr. Elmaleh, developed a parallel path for trapping fatty acid degradation via the beta-oxidation process, for which Professor Feodor Lynen received a Nobel Prize in 1964. Beta-methyl modified fatty acid, (BMIPP) is a commercially successful cardiac SPECT agent in Japan and Europe. He has also played a role in the development of Altropane, a Parkinson’s disease diagnostic agent (nominated as one of the 25 most valuable inventions of the brain decade by associated universities) that has completed Phase III clinical trials, several novel agents for early detection of dopamine and serotonin targeting drugs, and reversible acetyl choline esterase inhibitors. He also developed a new approach for molecular imaging with oligonucleotides and siRNA by facilitating the delivery to transformed cells using small molecular structures.

Dr. Elmaleh is a founder of several biotech companies including Molecular Insight (formerly Biostream) and Mersana (formerly NanoPharma) that recently closed a drug deals for over $700 million with big pharma. He also co-founded Puretech health that recently went public on The London Stock Exchange, at a valuation over $500 million.

Dr. Elmaleh holds a BS in Physics and Chemistry, and an MS and PhD in Organic Chemistry. Dr. Elmaleh is a recipient of numerous NIH and DOE grants. His recent work includes extensive research on imaging compounds, platforms to improve the speed and effectiveness of cardiovascular disease diagnosis, ischemia, infarction, and plaque formation which have enabled several drug technologies licensed from MGH to a new start-up. He is a co-author on over 130 publications and book chapters, an inventor of over 50 issued and pending patents in a range of disciplines, including molecular imaging and pharmaceuticals.

Dr. Peter Conti is a Professor of Radiology, Biomedical Engineering and Pharmacy at the University of Southern California. He has been the Director of the USC PET Imaging Science Center since its inception in 1991. He served as the President of the Society of Nuclear Medicine and is a major contributor to the development of clinical PET and molecular imaging. Dr. Conti is Board Certified in both Diagnostic Radiology and Nuclear Medicine. He received both his MD and PhD degrees from Cornell University.

Dr. Ronald Tompkins is the Sumner M. Redstone Professor of Surgery at the Harvard Medical School, the Chief of the Burns Service of the Massachusetts General Hospital (MGH), the Chief of Staff-Emeritus of the Shriners Hospitals for Children-Boston, and currently heads a new Institute for Innovation at MGH. He received a Bachelor of Science degree in Chemistry from Tulane University, an MD from Tulane Medical School, and a ScD degree in medical and chemical engineering from the Massachusetts Institute of Technology. Dr. Tompkins has published more than 400 contributions to the medical literature. His research interests include the metabolic and inflammatory responses to injury and tissue engineering.

John Porter is the Chairman of SinoCare Group, Hong Kong and Beijing. He specializes in starting and building medical and technology businesses. He founded SinoCare, which currently owns and operates five hospitals in China. Mr. Porter has helped to develop a number of public and privately owned companies including VeriFone, Telos, Bpure and Cast Alloys. He is on the board of advisors for Said Business School, Oxford University and a governor of Tel Aviv University. He is also a trustee of the Porter Foundation and President of the Earth Focus Foundation, Geneva. John was educated at Oxford, the Institute d’Etudes Politiques in Paris, and Stanford University.

Mr. Greenfield is a serial entrepreneur who has been involved in launching and advancing several biotech companies. Mr. Greenfield is the President of The Dover Group, a financial services provider. In addition to being a founder of Seroton Inc. and joining the Board of Directors of AZTherapies, Mr. Greenfield is assisting the Company with its business development related initiatives. Previously, Mr. Greenfield worked with Dr. Elmaleh as a founder of Imaging Biopharmaceutical and Zebra Pharmaceutical which later merged into Biostream prior to going public as Molecular Insight at a $340 million pre-money valuation. Mr. Greenfield has been a co-founder and director of a number of biotechnology and healthcare related companies. Most recently, Mr. Greenfield was a co-founder, director and EVP of Corporate Development at IQuum, Inc., a medical diagnostic company that was sold to Roche in 2014 for over $400 million.

David A. Taft has been a member of our board of directors since February, 2015. Mr. Taft is the President of IBS Capital LLC, an investment firm based in Boston, Massachusetts. Through IBS Capital, Mr. Taft manages several investment funds which pursue a value oriented, “event-driven” strategy. Mr. Taft has over 30 years of experience in the capital markets and is a member of The Boston Security Analysts Society and the CFA Institute. Mr. Taft graduated cum laude from Amherst College with a double major in Economics and Political Science in 1979 and earned his MBA from The Amos Tuck School at Dartmouth College in 1983.